Searchable abstracts of presentations at key conferences in endocrinology

ea0090p65 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Gender differences in smoking cessation? Results of a randomized controlled trial of dulaglutide-assisted smoking cessation

Baur Fabienne , David Coynel , Atila Cihan , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Bathelt Cemile , Christ-Crain Mirjam , Winzeler Bettina

Introduction: Smoking harms women more than men and women seem to be less successful in quitting. Greater concerns about post-cessational weight in women and gender differences in craving and reward processing have been postulated as possible explanations. Our group recently showed that the GLP-1 analogue dulaglutide reduces post-cessational weight gain. We hypothesize that women compared to men might profit more from the weight-lowering effects of dulaglutide in terms of abst...

ea0090p422 | Pituitary and Neuroendocrinology | ECE2023

Effects of a GLP-1 agonist on consumption of alcohol in patients treated for smoking cessation

Sofia Probst Leila , Monnerat Sophie , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Bathelt Cemile , Christ-Crain Mirjam , Winzeler Bettina

Introduction: Alcohol use disorder AUD causes high socio-economic costs and has a detrimental impact on health globally, being considered a key risk factor for non-communicable diseases. In Switzerland, four substances are currently approved for treatment of AUD, with varying effects. Taking into consideration the complex nature of the disease and the heterogeneity of affect patients, it becomes evident that there is need for new treatment targets. A body of preclinical studie...

ea0099p549 | Pituitary and Neuroendocrinology | ECE2024

Effects of glucagon-like peptide-1 analogs on prolactin: a randomized, double-blind, placebo-controlled crossover trial

Muller Cyrill , Lengsfeld Sophia , Probst Leila , Baur Fabienne , Yara Emara , Werlen Laura , Vogt Deborah , Bathelt Cemile , Winzeler Bettina

Background: Research indicates that prolactin, a hormone linked to lactation, may influence the brainÂ’s reward system by interacting with dopamine. GLP-1 analogues, prescribed for diabetes and obesity, are known for their appetite-suppressant effects. With GLP-1 receptors found in mood and reward-related brain regions, a potential role of GLP-1 in reward regulation is suggested. A knowledge gap exists regarding the interaction between GLP-1 and prolactin in the context of...

ea0090p69 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial

Lengsfeld Sophia , Hasenbohler Flavia , Probst Leila , Baur Fabienne , Emara Yara , Bathelt Cemile , Werlen Laura , Vogt Deborah , Caviezel Brida , Vukajlovic Tanja , Christ-Crain Mirjam , Winzeler Bettina

Background: GLP-1 analogs are prescribed for diabetes and obesity due to their well-known insulinotropic, satiation-promoting and appetite-suppressant effects. Several studies also investigated the effects of GLP-1 analogs on reward to addictive drugs such as alcohol, nicotine and cocaine. Pre-clinical studies suggest that sexual desire, as another type of natural reward, could also be affected by GLP-1 analogs. Since sexuality is a very important aspect of human wellbeing and...

ea0037gp.17.06 | Pituitary–Neuroendocrinology and central salt regulation | ECE2015

Predictors of response to fluid restriction in hyponatremic patients due to the syndrome of inappropriate antidiuresis

Lengsfeld Sophia , Winzeler Bettina , Nigro Nicole , Suter-Widmer Isabelle , Schutz Philipp , Arici Birsen , Bally Martina , Blum Claudine , Bock Andreas , Huber Andreas , Muller Beat , Christ-Crain Mirjam

Introduction: Fluid restriction (FR) is often the recommended first-line treatment for hyponatremia due to the syndrome of inappropriate antidiuresis (SIAD). However, FR not always leads to successful correction of hyponatremia, making predictive markers of treatment response desirable. The aim of this study was to evaluate routinely measured laboratory parameters, copeptin and pro-atrial natriuretic peptide (pro-ANP) as possible predictors of treatment success to FR.<p cl...

ea0099p31 | Adrenal and Cardiovascular Endocrinology | ECE2024

Blood pressure changes during smoking cessation on dulaglutide and placebo treatment – a secondary analysis of the randomized, double-blind, placebo-controlled SKIP trial

Julia Beck , Hasenbohler Flavia , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Bathelt Cemile , Vogt Deborah , Werlen Laura , Christ-Crain Mirjam , Winzeler Bettina

Objective: Smoking is an established major risk for atherosclerosis and cardiovascular mortality. However, the impact of smoking cessation on blood pressure remains controversial. Despite strong evidence linking smoking cessation to reduced cardiovascular risk, conflicting studies suggest potential increases in blood pressure after smoking cessation. Post cessational weight gain may contribute to these confliciting findings. We have recently shown that the glucagon-like peptid...

ea0081p76 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP – a randomised controlled study

Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Steinmetz Michelle , Sailer Clara , Coynel David , Vogt Deborah R , Hemkens Lars G. , Speich Benjamin , Kuhne Jill , Baur Fabienne , Lutz Linda , Bathelt Cemile , Zanchi Davide , Christ-Crain Mirjam , Winzeler Bettina

Background: Cigarette smoking is the leading preventable cause of premature death. Smoking cessation is one of the central goals in medicine, but despite dedicated programs, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behavior. These GLP-1 properties are of major interest in the context of smoking cessation....